William Blair issued their Q1 2026 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a report released on Wednesday, February 19th. William Blair analyst M. Minter forecasts that the ...

Allworth Financial LP lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 53.6% during the fourth quarter, Holdings Channel reports. The firm owned 548 shares of the ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Earnings included compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 43 cents against a gain of 12 cents per share in the year-ago quarter.

In this episode, we reflect upon recent events, including our delicious Thanksgiving, Shane’s latest Spinraza injection, ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a ...

Ionis Pharmaceuticals (NASDAQ:IONS) stock gains as company reports strong Q4 results fueled by new product rollouts like ...

During Q4, Ionis reported revenues of $227 million, 68.1% above the $135 million estimated by analysts. That positive surprise was attributed in part to the successful launch and commercialization of ...

A pioneering team at St Jude Children's Research Hospital in the US say they successfully treated a child diagnosed with SMA ...

Citi analyst David Lebowitz lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $67 and keeps a Buy rating on the ...